Lawrence Eichenfield News Today

Lawrence Eichenfield, MD, of Rady Children's Hospital - San Diego, discusses the implications of the findings from INTEGUMENT-PED, the phase 3 study assessing the efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients with atopic dermatitis (AD).

-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer-- Industry veterans and leading academic experts ...

-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer

These findings, to be presented at AAAAI, may allow for greater awareness among clinicians when prescribing eczema therapies.

In this interview, Eichenfield discussed the recent pooled analysis from two phase 3 studies looking at once-daily, topical roflumilast for patients 6 and older with eczema.

The clinic is a collaborative effort between Rady Children's Hospital and the University of California San Diego Health Divisions of Dermatology, Allergy & Immunology, and the hospital's pharmacy.

These data, presented at the Winter Clinical conference, showed that roflumilast cream 0.15% led to positive results for patients with eczema.

The Dermatology Month in Review for dermatology features 2 interviews, findings from recent long-term data, and a discussion of the FDA’s approval of secukinumab for HS.

This discussion with Dr. Eichenfield featured coverage of data on ruxolitinib for eczema patients.

In this interview with Dr. Eichenfield, comparisons between ruxolitinib and other treatments for eczema were discussed.